Nanotechnology and Alzheimer’s Disease


Аvera Allen, Deputy Editor In Chief

Date: 16.04.2021

University of Manchester scientists have discovered previously unseen blood biomarkers which could one day be used to test for Alzheimer’s disease, years before its symptoms appear.

The ground-breaking study, published in ACS Nano, used cutting-edge nanotechnology uniquely developed and patented by the Nanomedicine Lab in Manchester, to extract blood signals of neurodegeneration in a mouse model of Alzheimer’s disease. The study was funded by the Medical Research Council.

Tests that capture early signs of neurodegeneration in blood offer enormous potential for Alzheimer’s disease and other dementia patients to receive effective treatment or manage effectively their progressive condition before significant brain damage occurs.

Today, Alzheimer’s disease can be diagnosed by imaging techniques - brain scans - and is only possible after someone has been showing behavioural symptoms, such as memory impairment.

By the time symptoms emerge however, the pathology is already well-established in the brain - when it is often too late to treat patients effectively.

Though early markers of Alzheimer’s disease are believed to be present in blood, their minute levels make it extremely difficult to detect them - like looking for a needle in a haystack.

But thanks to the technology developed by the Manchester team, low blood signals that could non-invasively describe the onset of Alzheimer’s disease can now be magnified and analysed.

By Аvera Allen | Linkedin

Views: 57

Leave a request

Select option
Thank you, application submitted.